York-based life sciences specialist Aptamer Group, which develops molecular binders as an alternative to antibodies, has reported revenue growth of about 150 per cent in its full-year trading update.
The company will report revenue for the year ended 30 June 2022 of around £4m, in line with market expectations.
The business says its growth is due to strong operational performance, including contract wins and extensions across all three of its business units.
Arron Tolley, chief executive officer, said: “We are pleased with the pace of progress over the past six months, having seen success in expanding our current partnerships and winning new contracts, which has delivered financial performance in line with market expectations.
“We are anticipating growing demand as Pharma and Biotech increasingly outsource the development of enhanced binders for delivery of new generations of therapeutics.”
The company also plans to increase headcount and move into new, larger premises with increased automation by the end of 2022. The move will allow it to scale operations and streamline workflows in anticipation of increased demand for its products from new and existing customers alike.
Aptamer listed on AIM in December 2021, raising £10.8m.
